Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) | Enfermedades Infecciosas y Microbiología Clínica

array:23 ["pii" => "S0213005X18302271" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2018.06.014" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "1894" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "copyrightAnyo" => "2018" "documento" => "article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Enferm Infecc Microbiol Clin. 2020;38:28-32" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 828 "formatos" => array:2 [ "HTML" => 495 "PDF" => 333 ] ] "itemSiguiente" => array:19 [ "pii" => "S0213005X19301910" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2019.05.009" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "2039" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Enferm Infecc Microbiol Clin. 2020;38:33-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 405 "formatos" => array:2 [ "HTML" => 319 "PDF" => 86 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "Diagnóstico a primera vista" "titulo" => "Absceso en mano de etiología inusual" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "33" "paginaFinal" => "35" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Complicated abscess by uncommon etiology" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1016 "Ancho" => 2167 "Tamanyo" => 275068 ] ] "descripcion" => array:1 [ "es" => "A) Absceso de palma de la mano con celulitis y linfangitis. B) Colonias algodonosas, lanosas, de coloración marrón central y margen más claro e irregular en CNA a las 48 h de la incubación. El color de la figura solo puede apreciarse en la versión electrónica del artículo." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "C. Alicia García-Gutiérrez, Víctor Chan Moi Fat, Antonio Puerta-Mateo, María Soledad Cuétara" "autores" => array:4 [ 0 => array:2 [ "nombre" => "C. Alicia" "apellidos" => "García-Gutiérrez" ] 1 => array:2 [ "nombre" => "Víctor" "apellidos" => "Chan Moi Fat" ] 2 => array:2 [ "nombre" => "Antonio" "apellidos" => "Puerta-Mateo" ] 3 => array:2 [ "nombre" => "María Soledad" "apellidos" => "Cuétara" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529993X1930228X" "doi" => "10.1016/j.eimce.2019.05.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X1930228X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X19301910?idApp=UINPBA00004N" "url" => "/0213005X/0000003800000001/v1_202001061158/S0213005X19301910/v1_202001061158/es/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0213005X19301557" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2019.03.007" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "2016" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Enferm Infecc Microbiol Clin. 2020;38:25-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 664 "formatos" => array:2 [ "HTML" => 548 "PDF" => 116 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "Original breve" "titulo" => "Actividad in vitro de la combinación de ceftarolina con otros antimicrobianos activos frente a Staphylococcus spp" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "25" "paginaFinal" => "27" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "In vitro activity of ceftaroline in combination with other antimicrobials active against Staphylococcus spp" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Yolanda Gil Romero, José-Luis Gómez-Garcés" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Yolanda" "apellidos" => "Gil Romero" ] 1 => array:2 [ "nombre" => "José-Luis" "apellidos" => "Gómez-Garcés" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529993X19302242" "doi" => "10.1016/j.eimce.2019.03.009" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X19302242?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X19301557?idApp=UINPBA00004N" "url" => "/0213005X/0000003800000001/v1_202001061158/S0213005X19301557/v1_202001061158/es/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "Consensus statement" "titulo" => "Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "28" "paginaFinal" => "32" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Antonio Rivero-Juárez, Antonio Aguilera, Ana Avellón, Miguel García-Deltoro, Federico García, Christian Gortazar, Rafael Granados, Juan Macías, Nicolás Merchante, José Antonio Oteo, María Teresa Pérez-Gracia, Juan Antonio Pineda, David Rodriguez-Lazaro, Francisco Téllez, Luis E. Morano-Amado" "autores" => array:17 [ 0 => array:4 [ "nombre" => "Antonio" "apellidos" => "Rivero-Juárez" "email" => array:1 [ 0 => "arjvet@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Antonio" "apellidos" => "Aguilera" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Ana" "apellidos" => "Avellón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Miguel" "apellidos" => "García-Deltoro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "Federico" "apellidos" => "García" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "Christian" "apellidos" => "Gortazar" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] ] ] 6 => array:3 [ "nombre" => "Rafael" "apellidos" => "Granados" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "g" "identificador" => "aff0035" ] ] ] 7 => array:3 [ "nombre" => "Juan" "apellidos" => "Macías" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "aff0040" ] ] ] 8 => array:3 [ "nombre" => "Nicolás" "apellidos" => "Merchante" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "aff0040" ] ] ] 9 => array:3 [ "nombre" => "José Antonio" "apellidos" => "Oteo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "i" "identificador" => "aff0045" ] ] ] 10 => array:3 [ "nombre" => "María Teresa" "apellidos" => "Pérez-Gracia" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "j" "identificador" => "aff0050" ] ] ] 11 => array:3 [ "nombre" => "Juan Antonio" "apellidos" => "Pineda" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "aff0040" ] ] ] 12 => array:3 [ "nombre" => "Antonio" "apellidos" => "Rivero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 13 => array:3 [ "nombre" => "David" "apellidos" => "Rodriguez-Lazaro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "k" "identificador" => "aff0055" ] ] ] 14 => array:3 [ "nombre" => "Francisco" "apellidos" => "Téllez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "l" "identificador" => "aff12" ] ] ] 15 => array:3 [ "nombre" => "Luis E." "apellidos" => "Morano-Amado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "m" "identificador" => "aff0060" ] ] ] 16 => array:2 [ "colaborador" => "Grupo redactor de GeHEP SEIMC" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "◊" "identificador" => "fn0005" ] ] ] ] "afiliaciones" => array:13 [ 0 => array:3 [ "entidad" => "Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Complexo Hospitalario Universitario Santiago (CHUS) & Universidad de Santiago, Santiago de Compostela, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Consorcio General Hospital Universitario de Valencia, Valencia, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria IBS, Granada, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Instituto de Investigación en Recursos Cinegéticos (IREC-CSIC-UCLM), Ciudad Real, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Hospital Universitario Virgen de Valme, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain" "etiqueta" => "h" "identificador" => "aff0040" ] 8 => array:3 [ "entidad" => "Hospital Universitario San Pedro, Logroño Centro de investigación Biomédica de La Rioja (CIBIR), Spain" "etiqueta" => "i" "identificador" => "aff0045" ] 9 => array:3 [ "entidad" => "Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Valencia, Spain" "etiqueta" => "j" "identificador" => "aff0050" ] 10 => array:3 [ "entidad" => "Facultad de Ciencias, Universidad de Burgos, Burgos, Spain" "etiqueta" => "k" "identificador" => "aff0055" ] 11 => array:3 [ "entidad" => "Hospital Universitario Puerto Real, Cádiz, Spain" "etiqueta" => "l" "identificador" => "aff12" ] 12 => array:3 [ "entidad" => "Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, Vigo, Spain" "etiqueta" => "m" "identificador" => "aff0060" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Resumen ejecutivo: Documento de consenso del Grupo de Estudio de las Hepatitis Víricas perteneciente a la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica sobre el diagnóstico, manejo y prevención de la infección por el virus de la hepatitis E" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2148 "Ancho" => 1583 "Tamanyo" => 233590 ] ] "descripcion" => array:1 [ "en" => "Proposed algorithm for the management of HEV infection." ] ] ] "textoCompleto" => "Justification and scopeHepatitis E virus (HEV) infection is one of the main causes of acute hepatitis in both developed and developing countries. This infectious disease has a high prevalence and incidence in Europe.<a class="elsevierStyleCrossRef" href="#bib0050">1</a> HEV infection has a greater clinical impact in vulnerable populations, such as immunosuppressed patients, pregnant women, and patients with underlying liver disease.<a class="elsevierStyleCrossRefs" href="#bib0055">2,3</a> Thus, the World Health Organisation (WHO) ranks it as one of the leading causes of death due to acute hepatitis of viral origin worldwide.<a class="elsevierStyleCrossRef" href="#bib0065">4</a> However, national and international recommendations for the screening, diagnosis, and treatment of HEV have not been developed (EASL guidelines has been reported after submission of the present document),<a class="elsevierStyleCrossRef" href="#bib0070">5</a> which makes it difficult to manage patients. This, combined with the fact that HEV infection is not a notifiable disease in most countries, allows us to speculate that its incidence and clinical impact may be higher than expected. The European Food Safety Authority (EFSA) has indicated that HEV infection is a major public health problem in Europe because the infection is transmitted efficiently by the consumption of contaminated animal foods (mainly pork and game meat), and there are no protocols or specific plans for prevention in animal production or in food production chains.<a class="elsevierStyleCrossRef" href="#bib0075">6</a> Finally, there are no recommendations for the screening of this disease in blood, tissue, or organ donors, which may cause this route to be an important source of disease transmission.<a class="elsevierStyleCrossRefs" href="#bib0080">7,8</a>By these reasons, the Grupo de Estudio de Hepatitis Víricas (GEHEP) of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) considered it very important to prepare a Consensus Document to help in decision making about the diagnosis, clinical, therapeutic management, and prevention of HEV infection. The panel of experts for the preparation of this document is composed of HEV infection experts in the areas of clinical management, diagnostic microbiology, food technology, and veterinary medicine. The recommendations in these guides are based on scientific evidence. The strength of the recommendation and grading of the evidence that supports it are based on a modification of the criteria of the Infectious Diseases Society of America.<a class="elsevierStyleCrossRef" href="#bib0090">9</a> According to these criteria, each recommendation must always be offered (A), in general (B), or optionally (C), and must be based on data obtained from one or more randomised clinical trials with clinical or laboratory results (I), one or more nonrandomised trials or observational cohort studies (II), or the opinion of experts (III).Who should be screened for the hepatitis E virus?Screening in patients with acute or chronic hepatitisRecommendations<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">•All patients with acute hepatitis should be screened for HEV infection (AII).</li><li class="elsevierStyleListItem" id="lsti0010">•All patients with acute liver failure (ALF) should be screened for HEV infection (AII).</li><li class="elsevierStyleListItem" id="lsti0015">•In patients with known or recently diagnosed chronic liver disease with decompensation and/or data suggestive of acute liver inflammation HEV should be screened (AII).</li><li class="elsevierStyleListItem" id="lsti0020">•HEV screening should be included in the diagnostic of chronic hepatitis (AII).</li><li class="elsevierStyleListItem" id="lsti0025">•In patients with unexplained liver disease HEV screening should performed (AII).</li><li class="elsevierStyleListItem" id="lsti0030">•In patients with suspected drug-induced hepatitis, HEV screening should be performed (BII).</li></ul>Screening of HEV in blood and/or organ donorsRecommendations<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0035">•HEV screening should be performed on all organ donors, living or deceased (AII).</li><li class="elsevierStyleListItem" id="lsti0040">•Studies on the prevalence of HEV infection in blood donations should be conducted across the different areas of blood bank influence to adapt HEV screening strategies to the prevalence of HEV infection in each area (AII).</li></ul>Screening of HEV in patients with extra-hepatic manifestationsRecommendations<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0045">•In patients with any of the extrahepatic clinical manifestations that have been associated with HEV infection (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>), screening for HEV infection should performed, even in the absence of liver abnormalities (BII).<elsevierMultimedia ident="tbl0005"></elsevierMultimedia></li></ul>Screening in contacts of HEV casesRecommendations<ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0050">•The study of the close contacts of a case with documented HEV infection is not recommended, except in a case where they share a source of infection with the case (AII).</li></ul>How is hepatitis E virus infection diagnosed?The virological markers for the diagnosis of HEV infection comprise components of the viral structure, such as nucleic acid (HEV-RNA) and the viral antigen (HEV-Ag), and products of the host immune response, such as Anti-HEV specific antibodies of classes IgA, IgG, and IgM. These virological markers are the basis not only for diagnosis but also for monitoring treatment, and they permit the characterisation of the natural history of hepatitis E in its different phases: acute, recent, resolved or past, and chronic. The principal markers of acute HEV infection are HEV-RNA, HEV-Ag, Anti-HEV-IgM, and -IgA; increasing titres or low affinity of Anti-HEV-IgG antibodies are also indicative of acute HEV infection. However, these markers appear at different times, persist for different periods, and differ in their meaning in the clinical diagnosis. Therefore, regardless of whether the high titres or low affinity of Anti-HEV-IgG-specific antibodies can be considered suggestive of acute HEV infection, their mere presence should not be considered a diagnostic criterion. Consequently, any diagnostic algorithm of HEV infection (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>) should be based mainly on the presence of Anti-HEV-IgM-specific antibodies and/or the presence of HEV-Ag and HEV-RNA infectivity markers. The diagnosis of chronic HEV infection is usually based almost exclusively on the presence of HEV-RNA in the blood or other body fluids for more than 3 months, whereas that of resolved infection is characterised by the isolated presence of Anti-HEV-IgG antibodies.<elsevierMultimedia ident="tbl0010"></elsevierMultimedia>Recommendations<ul class="elsevierStyleList" id="lis0025"><li class="elsevierStyleListItem" id="lsti0055">•The diagnosis of acute HEV infection in immunocompetent individuals is based on the presence of Anti-HEV-IgM and/or HEVRNA (AII).</li><li class="elsevierStyleListItem" id="lsti0060">•In laboratories that do not have adequate technology for molecular diagnosis, despite its lower sensitivity, it's recommended the detection of HEV-Ag as alternative, as a direct method for the diagnosis of HEV infection (AIII).</li><li class="elsevierStyleListItem" id="lsti0065">•Although it lacks diagnostic utility, the characterisation of HEV at the genotype and subtype levels through direct or new generation sequencing and subsequent phylogenetic analysis may be important for studies of the molecular epidemiology of HEV infection (AII).</li><li class="elsevierStyleListItem" id="lsti0070">•Quality control systems based on WHO standards should be established, and reagents available for this purpose for the standardisation of the different results obtained in molecular and serological techniques should be determined (BII).</li></ul>Who to treat and how to treat hepatitis E virus infection?The treatment of HEV infection varies depending on the immunological situation of the patient and the clinical presentation of the infection (acute vs chronic). If indicated, the treatment objective is to eradicate HEV, which is determined by the achievement of a sustained viral response (SVR), defined as the absence of HEV-RNA at 12 weeks after the end of treatment. For this, the absence of HEV-RNA in both the serum and the faeces should be confirmed. <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a> shows the proposed algorithm for treatment of chronic HEV infection.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>Treatment of acute hepatitis ERecommendations<ul class="elsevierStyleList" id="lis0030"><li class="elsevierStyleListItem" id="lsti0075">•Antiviral treatment for acute hepatitis E should be considered in patients with liver cirrhosis or immunosuppression from any cause (BII). If treatment is indicated, this will consist of RBV adjusted for weight (1000mg if <75kg or 1200mg if >75kg) for 3 months (AII).</li></ul>Treatment of chronic hepatitis ERecommendations<ul class="elsevierStyleList" id="lis0035"><li class="elsevierStyleListItem" id="lsti0080">•In patients with pharmacological immunosuppression and chronic hepatitis due to HEV, immunosuppressive therapy should be reduced or discontinued if the clinical situation permits. The persistence of HEV-RNA in the blood and faeces should be reevaluated at 12 weeks (AII).</li><li class="elsevierStyleListItem" id="lsti0085">•In the case of persistent HEV-RNA after the reduction of immunosuppression or in those cases in which this measure is not feasible, antiviral treatment should be initiated (AII).</li><li class="elsevierStyleListItem" id="lsti0090">•In immunosuppressed patients of non-pharmacological causes, such as HIV-infected individuals, antiviral treatment should be considered from the beginning (AII).</li><li class="elsevierStyleListItem" id="lsti0095">•The antiviral treatment will consist of the administration of RBV 600mg per day for 12 weeks (AII).</li><li class="elsevierStyleListItem" id="lsti0100">•At 4 weeks, the presence of HEV-RNA in the serum should be evaluated, and treatment should be prolonged to 24 weeks if the viral load is positive (BII).</li><li class="elsevierStyleListItem" id="lsti0105">•If the viral load at week 4 is negative, the presence of HEV-RNA in the faeces and serum should be evaluated after 12 weeks of treatment, and treatment can be suspended if HEV clearance has occurred (BII).</li><li class="elsevierStyleListItem" id="lsti0110">•In the case of viral persistence, treatment should be continued until completing 24 weeks (BII).</li><li class="elsevierStyleListItem" id="lsti0115">•In all cases, the presence of HEV-RNA in the faeces and serum should be evaluated 12 weeks after completing treatment (AII).</li><li class="elsevierStyleListItem" id="lsti0120">•In the absence of SVR after a previous 12-week treatment, retreatment with RBV should be considered for 24 weeks (BIII).</li><li class="elsevierStyleListItem" id="lsti0125">•In those patients with an absence of SVR after treatment with RBV for 24 weeks, there are no current alternative treatment options that can be recommended, except for pegylated interferon in the specific scenario of liver transplantation (CIII).</li></ul>Treatment of hepatitis E derived extrahepatic manifestationsRecommendations<ul class="elsevierStyleList" id="lis0040"><li class="elsevierStyleListItem" id="lsti0130">•Given the suspicion of extrahepatic manifestations related to HEV infection, antiviral treatment with RBV can be considered following the same guidelines as for chronic hepatitis E (CIII).</li></ul>How should we follow-up on a patient diagnosed with hepatitis E virus infection?HEV infection, which depends in large part on the characteristics of the host and the virus itself, can evolve in an acute or chronic manner as well as present a wide range of clinical manifestations, ranging from asymptomatic or subclinical to fulminant hepatitis, with or without extrahepatic manifestations. Thus, an individualised clinical follow up is required for each patient (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>).<elsevierMultimedia ident="fig0010"></elsevierMultimedia>Follow-up of acute infectionRecommendations<ul class="elsevierStyleList" id="lis0045"><li class="elsevierStyleListItem" id="lsti0135">•Follow up is recommended for immunocompetent patients with acute HEV infection over 12 weeks to determine HEV-RNA status at the end of this period (AII).</li><li class="elsevierStyleListItem" id="lsti0140">•It is recommended that patients with acute HEV infection with clinical evidence of liver failure be admitted to an intensive care unit to start HEV treatment (AIII).</li><li class="elsevierStyleListItem" id="lsti0145">•Weekly liver function tests and close foetal monitoring are recommended for pregnant women with acute HEV infection under gynaecological advice (AII).</li><li class="elsevierStyleListItem" id="lsti0150">•Formula-feeding is recommended for women with acute or chronic HEV infection (CIII).</li></ul>Follow-up of chronic infectionRecommendations<ul class="elsevierStyleList" id="lis0050"><li class="elsevierStyleListItem" id="lsti0155">•It is recommended that patients with chronic HEV infection and SVR with persistent immunosuppression receive biannual HEV-RNA treatment during the first year (AII).</li><li class="elsevierStyleListItem" id="lsti0160">•The annual determination of HEV-RNA in the blood is recommended for immunocompromised patients in whom, after reaching SVR, the risk of exposure to HEV is maintained (professional...), given the risk of reinfection (BII).</li><li class="elsevierStyleListItem" id="lsti0165">•Biannual ultrasound tests are recommended indefinitely for hepatocarcinoma screening amongst patients with chronic HEV infection and stage F3 or F4 liver fibrosis, even after reaching SVR (CIII).</li></ul>Follow-up of infection with extrahepatic manifestationsRecommendations<ul class="elsevierStyleList" id="lis0055"><li class="elsevierStyleListItem" id="lsti0170">•Treatment and follow up of HEV infection is recommended for cases of extrahepatic manifestations following the same recommendations cited for acute or chronic infection, depending on the case (CIII).</li></ul>What measures should be recommended for preventing infection with the hepatitis E virus?The risk of acquiring HEV infection varies depending on the geographical location and the genotypes circulating in each region. Similar to all other communicable diseases, the simplest measures for preventing them are based on avoiding contact with sources of infection. In Europe, the main HEV exposure routes come from the intake of pork products, insufficiently cooked game animals (particularly the livers), and blood transfusions and their derivatives [4, 26, 122]. In travellers to developing countries in Asia, Africa, and Latin America and in the inhabitants of these countries, infections are also produced by this zoonotic route, although the main source is contaminated water and the products contaminated by it, causing large epidemic outbreaks. Considering these facts, it is essential to conduct information and awareness campaigns in the general population and amongst health workers, emphasising the acquisition pathways. Advice should be offered to the general population and, particularly in our setting, to immunosuppressed people and people who have chronic liver disease, because of the high risk of the infection becoming chronic or of having an accelerated or serious course of infection.General measures in the general population and the immunosuppressed populationRecommendations<ul class="elsevierStyleList" id="lis0060"><li class="elsevierStyleListItem" id="lsti0175">•The prevention of HEV infection should be based on offering information aimed at avoiding contact with sources of infection (AII).</li><li class="elsevierStyleListItem" id="lsti0180">•On trips to developing countries, to avoid contact with HEV, general hygienic practices should be adopted, such as washing the hands with clean or sanitised water before handling food. Do not drink water or consume ice of unknown purity. The consumption of fruit not peeled by oneself and of raw foods in general should be avoided (AII).</li><li class="elsevierStyleListItem" id="lsti0185">•In addition to adopting the basic hygienic measures recommended for the general population, people at high risk of developing a severe course of infection or the chronification of it (cirrhotic and transplanted) must be specifically informed of the risk involved in eating pork products and undercooked game animals, including sausages, and to avoid the consumption of these products (AII).</li><li class="elsevierStyleListItem" id="lsti0190">•People at high risk of developing a severe course of infection or the chronification of it should subject food to cooking-heating at a temperature≥70°C for a minimum of 30min (AI).</li></ul>Measures in other populations and contactsRecommendations<ul class="elsevierStyleList" id="lis0065"><li class="elsevierStyleListItem" id="lsti0195">•Given the serious and even fatal course that pregnant women may suffer, women travelling to areas of high endemicity of HEV genotypes 1 and 2 should receive information and should adhere to hygienic standards to avoid contact with HEV (AII).</li><li class="elsevierStyleListItem" id="lsti0200">•Patients suffering from acute or chronic HEV infection should use barrier measures in their sexual relations (AIII).</li><li class="elsevierStyleListItem" id="lsti0205">•Formula-feeding should be recommended in women with acute or chronic HEV infection (CIII).</li></ul>VaccinationRecommendations<ul class="elsevierStyleList" id="lis0070"><li class="elsevierStyleListItem" id="lsti0210">•There is a recombinant vaccine marketed in China (Hecolin®) that has been shown to be safe and effective in healthy people over 16 and under 65 years of age (AI).</li><li class="elsevierStyleListItem" id="lsti0215">•Routine vaccination is not recommended in children under 16 years old, people over 65 years old, patients with chronic liver disease, patients on solid organ transplant lists, pregnant women, or travellers (CIII).</li><li class="elsevierStyleListItem" id="lsti0220">•Vaccination should be considered individually in people who plan to travel to an area where an epidemic is occurring (e.g., aid workers and health workers) (CIII).</li></ul>Conflict of interestThere has been not funding from private institutions for the preparation of this document. The members of the Consensus Document panel have agreed to participate voluntarily and issue a declaration of conflicts of interest that can be found in the full document report (available at SEIMC web site)." "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres1283918" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1186520" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1283919" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1186519" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Justification and scope" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Who should be screened for the hepatitis E virus?" "secciones" => array:4 [ 0 => array:3 [ "identificador" => "sec0015" "titulo" => "Screening in patients with acute or chronic hepatitis" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Recommendations" ] ] ] 1 => array:3 [ "identificador" => "sec0025" "titulo" => "Screening of HEV in blood and/or organ donors" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0030" "titulo" => "Recommendations" ] ] ] 2 => array:3 [ "identificador" => "sec0035" "titulo" => "Screening of HEV in patients with extra-hepatic manifestations" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Recommendations" ] ] ] 3 => array:3 [ "identificador" => "sec0045" "titulo" => "Screening in contacts of HEV cases" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0050" "titulo" => "Recommendations" ] ] ] ] ] 6 => array:3 [ "identificador" => "sec0055" "titulo" => "How is hepatitis E virus infection diagnosed?" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0060" "titulo" => "Recommendations" ] ] ] 7 => array:3 [ "identificador" => "sec0065" "titulo" => "Who to treat and how to treat hepatitis E virus infection?" "secciones" => array:3 [ 0 => array:3 [ "identificador" => "sec0070" "titulo" => "Treatment of acute hepatitis E" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0075" "titulo" => "Recommendations" ] ] ] 1 => array:3 [ "identificador" => "sec0080" "titulo" => "Treatment of chronic hepatitis E" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0085" "titulo" => "Recommendations" ] ] ] 2 => array:3 [ "identificador" => "sec0090" "titulo" => "Treatment of hepatitis E derived extrahepatic manifestations" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0095" "titulo" => "Recommendations" ] ] ] ] ] 8 => array:3 [ "identificador" => "sec0100" "titulo" => "How should we follow-up on a patient diagnosed with hepatitis E virus infection?" "secciones" => array:3 [ 0 => array:3 [ "identificador" => "sec0105" "titulo" => "Follow-up of acute infection" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0110" "titulo" => "Recommendations" ] ] ] 1 => array:3 [ "identificador" => "sec0115" "titulo" => "Follow-up of chronic infection" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0120" "titulo" => "Recommendations" ] ] ] 2 => array:3 [ "identificador" => "sec0125" "titulo" => "Follow-up of infection with extrahepatic manifestations" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0130" "titulo" => "Recommendations" ] ] ] ] ] 9 => array:3 [ "identificador" => "sec0135" "titulo" => "What measures should be recommended for preventing infection with the hepatitis E virus?" "secciones" => array:3 [ 0 => array:3 [ "identificador" => "sec0140" "titulo" => "General measures in the general population and the immunosuppressed population" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0145" "titulo" => "Recommendations" ] ] ] 1 => array:3 [ "identificador" => "sec0150" "titulo" => "Measures in other populations and contacts" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0155" "titulo" => "Recommendations" ] ] ] 2 => array:3 [ "identificador" => "sec0160" "titulo" => "Vaccination" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0165" "titulo" => "Recommendations" ] ] ] ] ] 10 => array:2 [ "identificador" => "sec0170" "titulo" => "Conflict of interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2018-06-05" "fechaAceptado" => "2018-06-06" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1186520" "palabras" => array:10 [ 0 => "Hepatitis E" 1 => "Zoonoses" 2 => "Acute hepatitis" 3 => "Chronic hepatitis" 4 => "Pregnancy" 5 => "Neurological disorders" 6 => "Transplantation" 7 => "Ribavirin" 8 => "Pegylated interferon" 9 => "Prevention" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1186519" "palabras" => array:10 [ 0 => "Hepatitis E" 1 => "Zoonosis" 2 => "Hepatitis aguda" 3 => "Hepatitis crónica" 4 => "Embarazo" 5 => "Alteraciones neurológicas" 6 => "Trasplante" 7 => "Ribavirina" 8 => "Interferón pegilado" 9 => "Prevención" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis in both developed and developing countries. This infectious disease has a high prevalence and incidence in Europe. HEV infection has a greater clinical impact in vulnerable populations, such as immunosuppressed patients, pregnant women and patients with underlying liver disease. Therefore, the Study Group for Viral Hepatitis (Grupo de Estudio de Hepatitis Víricas, GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, SEIMC) believed it very important to prepare a consensus document to help in decision-making regarding diagnosis, clinical and therapeutic management, and prevention of HEV infection." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "La infección por el virus de la hepatitis E (VHE) es una de las principales causas de hepatitis aguda tanto en países desarrollados como en vías de desarrollo, situándose como una enfermedad infecciosa de alta prevalencia e incidencia en Europa. La infección por el VHE tiene mayor impacto clínico en poblaciones especialmente vulnerables, como pacientes inmunodeprimidos, mujeres embarazadas y pacientes con hepatopatía base. Por todo ello, desde el Grupo de Estudio de las Hepatitis Víricas (GeHEP) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) se considera de gran relevancia la elaboración de un Documento de Consenso que sirva de ayuda en la toma de decisiones sobre el diagnóstico, manejo clínico-terapéutico y la prevención de la infección por el VHE." ] ] "NotaPie" => array:1 [ 0 => array:3 [ "etiqueta" => "◊" "nota" => "The complete consensus statement is as supplementary material in <a class="elsevierStyleCrossRef" href="#sec0175">Appendix A</a>." "identificador" => "fn0005" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "The following are the supplementary data to this article:<elsevierMultimedia ident="upi0005"></elsevierMultimedia>" "etiqueta" => "Appendix A" "titulo" => "Supplementary data" "identificador" => "sec0180" ] ] ] ] "multimedia" => array:5 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1881 "Ancho" => 1583 "Tamanyo" => 179659 ] ] "descripcion" => array:1 [ "en" => "Recommended management algorithm for the treatment of chronic hepatitis E." ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2148 "Ancho" => 1583 "Tamanyo" => 233590 ] ] "descripcion" => array:1 [ "en" => "Proposed algorithm for the management of HEV infection." ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Acute pancreatitis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Haematological manifestations: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Thrombopenia, haemolysis, aplastic anaemia, cryoglobulinemia, monoclonal gammopathy \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Autoimmune phenomena: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Membranous glomerulonephritis, Henoch-Schönlein purpura, arthralgia, skin rash \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CNS neurological syndromes: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Transverse acute myelitis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Acute meningoencephalitis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Aseptic meningitis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Amyotrophic neuralgia \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Pseudotumour cerebri \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Bilateral pyramidal syndrome \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PNS neurological syndromes: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Guillain-Barré syndrome \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Cranial nerve paralysis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Peripheral neuropathy \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2199453.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Extrahepatic manifestations of HEV infection." ] ] 3 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n \t\t\t\t\ttable-head\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Anti-HEV-IgM<a class="elsevierStyleCrossRefs" href="#tblfn0005">a,c</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="3" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Positive</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="4" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative</th></tr><tr title="table-row"><th class="td-with-role" title="\n \t\t\t\t\ttable-head\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">HEV-RNA and/or HEV-Ag<a class="elsevierStyleCrossRef" href="#tblfn0010">b</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Positive \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Positive</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Anti-HEV-IgG<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Positive \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Positive \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Positive \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Interpretation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Acute infection Chronic infection (RNA+ >3 months) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Recent infection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cross-reactivity<a class="elsevierStyleCrossRef" href="#tblfn0015">c</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Acute infectionPossible reinfection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Window period Chronic infection (RNA+ >3 months) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Past infection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Absence of infection \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2199452.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Serum and/or plasma." ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "Serum, plasma, CSF, faeces, urine, etc." ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "c" "nota" => "Anti-HEV-IgM reactivity should be confirmed with immunoblotting and a subsequent seroconversion study." ] ] ] "descripcion" => array:1 [ "en" => "Diagnostic algorithm for HEV infection." ] ] 4 => array:5 [ "identificador" => "upi0005" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "Ecomponente" => array:2 [ "fichero" => "mmc1.pdf" "ficheroTamanyo" => 723773 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:9 [ 0 => array:3 [ "identificador" => "bib0050" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis E virus infection in Europe: surveillance and descriptive epidemiology of confirmed cases, 2005 to 2015" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.J. Aspinall" 1 => "E. Couturier" 2 => "M. Faber" 3 => "B. Said" 4 => "S. Ijaz" 5 => "L. Tavoschi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Euro Surveill" "fecha" => "2017" "volumen" => "22" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0055" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Kumar Acharya" 1 => "P. Kumar Sharma" 2 => "R. Singh" 3 => "S. Kumar Mohanty" 4 => "K. Madan" 5 => "J. Kumar Jha" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2006.09.016" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2007" "volumen" => "46" "paginaInicial" => "387" "paginaFinal" => "394" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17125878" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0060" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Patra" 1 => "A. Kumar" 2 => "S.S. Trivedi" 3 => "M. Puri" 4 => "S.K. Sarin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-147-1-200707030-00005" "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "2007" "volumen" => "147" "paginaInicial" => "28" "paginaFinal" => "33" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17606958" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0065" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "World Health Organization. Global hepatitis report, 2017. Available from: <a target="_blank" href="http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/">http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/</a>." ] ] ] 4 => array:3 [ "identificador" => "bib0070" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EASL Clinical Practice Guidelines on hepatitis E virus infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "European Association for the Study of the Liver" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2018.03.005" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2018" "volumen" => "68" "paginaInicial" => "1256" "paginaFinal" => "1271" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29609832" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0075" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Food Safety Authority. Public health risks associated with hepatitis E virus (HEV) as a food-borne pathogen. Available from: <a target="_blank" href="https://www.efsa.europa.eu/en/efsajournal/pub/4886">https://www.efsa.europa.eu/en/efsajournal/pub/4886</a>." ] ] ] 6 => array:3 [ "identificador" => "bib0080" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis E and blood donation safety in selected European countries: a shift to screening?" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Domanović" 1 => "R. Tedder" 2 => "J. Blümel" 3 => "H. Zaaijer" 4 => "P. Gallian" 5 => "C. Niederhauser" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Euro Surveill" "fecha" => "2017" "volumen" => "22" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0085" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Summary of the British Transplantation Society UK guidelines for hepatitis E and solid organ transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. McPherson" 1 => "A.M. Elsharkawy" 2 => "M. Ankcorn" 3 => "S. Ijaz" 4 => "J. Powell" 5 => "I. Rowe" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/TP.0000000000001908" "Revista" => array:6 [ "tituloSerie" => "Transplantation" "fecha" => "2018" "volumen" => "102" "paginaInicial" => "15" "paginaFinal" => "20" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28795981" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0090" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guide to development of practice guidelines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.A. Kish" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2001" "volumen" => "32" "paginaInicial" => "841" "paginaFinal" => "844" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/0213005X/0000003800000001/v1_202001061158/S0213005X18302271/v1_202001061158/en/main.assets" "Apartado" => array:4 [ "identificador" => "8681" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Documento de consenso" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/0213005X/0000003800000001/v1_202001061158/S0213005X18302271/v1_202001061158/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X18302271?idApp=UINPBA00004N"]

Estadísticas

Consensus statement

Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

Resumen ejecutivo: Documento de consenso del Grupo de Estudio de las Hepatitis Víricas perteneciente a la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica sobre el diagnóstico, manejo y prevención de la infección por el virus de la hepatitis E

Antonio Rivero-Juáreza,

Autor para correspondencia

arjvet@gmail.com

Corresponding author.

, Antonio Aguilerab, Ana Avellónc, Miguel García-Deltorod, Federico Garcíae, Christian Gortazarf, Rafael Granadosg, Juan Macíash, Nicolás Merchanteh, José Antonio Oteoi, María Teresa Pérez-Graciaj, Juan Antonio Pinedah, Antonio Riveroa, David Rodriguez-Lazarok, Francisco Téllezl, Luis E. Morano-Amadom, Grupo redactor de GeHEP SEIMC ◊

a Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain

b Complexo Hospitalario Universitario Santiago (CHUS) & Universidad de Santiago, Santiago de Compostela, Spain

c Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain

d Consorcio General Hospital Universitario de Valencia, Valencia, Spain

e Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria IBS, Granada, Spain

f Instituto de Investigación en Recursos Cinegéticos (IREC-CSIC-UCLM), Ciudad Real, Spain

g Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

h Hospital Universitario Virgen de Valme, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain

i Hospital Universitario San Pedro, Logroño Centro de investigación Biomédica de La Rioja (CIBIR), Spain

j Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Valencia, Spain

k Facultad de Ciencias, Universidad de Burgos, Burgos, Spain

l Hospital Universitario Puerto Real, Cádiz, Spain

m Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, Vigo, Spain

Leído

48458

Veces
se ha leído el artículo

1426

Total PDF

47032

Total HTML

Compartir estadísticas

 array:23 [
  "pii" => "S0213005X18302271"
  "issn" => "0213005X"
  "doi" => "10.1016/j.eimc.2018.06.014"
  "estado" => "S300"
  "fechaPublicacion" => "2020-01-01"
  "aid" => "1894"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica"
  "copyrightAnyo" => "2018"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "pgl"
  "cita" => "Enferm Infecc Microbiol Clin. 2020;38:28-32"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 828
    "formatos" => array:2 [
      "HTML" => 495
      "PDF" => 333
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S0213005X19301910"
    "issn" => "0213005X"
    "doi" => "10.1016/j.eimc.2019.05.009"
    "estado" => "S300"
    "fechaPublicacion" => "2020-01-01"
    "aid" => "2039"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Enferm Infecc Microbiol Clin. 2020;38:33-5"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 405
      "formatos" => array:2 [
        "HTML" => 319
        "PDF" => 86
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Diagn&#243;stico a primera vista</span>"
      "titulo" => "Absceso en mano de etiolog&#237;a inusual"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "33"
          "paginaFinal" => "35"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Complicated abscess by uncommon etiology"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1016
              "Ancho" => 2167
              "Tamanyo" => 275068
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A&#41; Absceso de palma de la mano con celulitis y linfangitis&#46; B&#41; Colonias algodonosas&#44; lanosas&#44; de coloraci&#243;n marr&#243;n central y margen m&#225;s claro e irregular en CNA a las 48 h de la incubaci&#243;n&#46; El color de la figura solo puede apreciarse en la versi&#243;n electr&#243;nica del art&#237;culo&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "C&#46; Alicia Garc&#237;a-Guti&#233;rrez, V&#237;ctor Chan Moi Fat, Antonio Puerta-Mateo, Mar&#237;a Soledad Cu&#233;tara"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "C&#46; Alicia"
              "apellidos" => "Garc&#237;a-Guti&#233;rrez"
            ]
            1 => array:2 [
              "nombre" => "V&#237;ctor"
              "apellidos" => "Chan Moi Fat"
            ]
            2 => array:2 [
              "nombre" => "Antonio"
              "apellidos" => "Puerta-Mateo"
            ]
            3 => array:2 [
              "nombre" => "Mar&#237;a Soledad"
              "apellidos" => "Cu&#233;tara"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2529993X1930228X"
        "doi" => "10.1016/j.eimce.2019.05.003"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X1930228X?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X19301910?idApp=UINPBA00004N"
    "url" => "/0213005X/0000003800000001/v1_202001061158/S0213005X19301910/v1_202001061158/es/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S0213005X19301557"
    "issn" => "0213005X"
    "doi" => "10.1016/j.eimc.2019.03.007"
    "estado" => "S300"
    "fechaPublicacion" => "2020-01-01"
    "aid" => "2016"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Enferm Infecc Microbiol Clin. 2020;38:25-7"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 664
      "formatos" => array:2 [
        "HTML" => 548
        "PDF" => 116
      ]
    ]
    "es" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original breve</span>"
      "titulo" => "Actividad <span class="elsevierStyleItalic">in vitro</span> de la combinaci&#243;n de ceftarolina con otros antimicrobianos activos frente a <span class="elsevierStyleItalic">Staphylococcus</span> spp"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "25"
          "paginaFinal" => "27"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "<span class="elsevierStyleItalic">In vitro</span> activity of ceftaroline in combination with other antimicrobials active against <span class="elsevierStyleItalic">Staphylococcus</span> spp"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Yolanda Gil Romero, Jos&#233;-Luis G&#243;mez-Garc&#233;s"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Yolanda"
              "apellidos" => "Gil Romero"
            ]
            1 => array:2 [
              "nombre" => "Jos&#233;-Luis"
              "apellidos" => "G&#243;mez-Garc&#233;s"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2529993X19302242"
        "doi" => "10.1016/j.eimce.2019.03.009"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X19302242?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X19301557?idApp=UINPBA00004N"
    "url" => "/0213005X/0000003800000001/v1_202001061158/S0213005X19301557/v1_202001061158/es/main.assets"
  ]
  "en" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Consensus statement</span>"
    "titulo" => "Executive summary&#58; Consensus document of the diagnosis&#44; management and prevention of infection with the hepatitis E virus&#58; Study Group for Viral Hepatitis &#40;<span class="elsevierStyleItalic">GEHEP</span>&#41; of the Spanish Society of Infectious Diseases and Clinical Microbiology &#40;<span class="elsevierStyleItalic">SEIMC</span>&#41;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "28"
        "paginaFinal" => "32"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Antonio Rivero-Ju&#225;rez, Antonio Aguilera, Ana Avell&#243;n, Miguel Garc&#237;a-Deltoro, Federico Garc&#237;a, Christian Gortazar, Rafael Granados, Juan Mac&#237;as, Nicol&#225;s Merchante, Jos&#233; Antonio Oteo, Mar&#237;a Teresa P&#233;rez-Gracia, Juan Antonio Pineda, David Rodriguez-Lazaro, Francisco T&#233;llez, Luis E&#46; Morano-Amado"
        "autores" => array:17 [
          0 => array:4 [
            "nombre" => "Antonio"
            "apellidos" => "Rivero-Ju&#225;rez"
            "email" => array:1 [
              0 => "arjvet@gmail.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Antonio"
            "apellidos" => "Aguilera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Ana"
            "apellidos" => "Avell&#243;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Miguel"
            "apellidos" => "Garc&#237;a-Deltoro"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Federico"
            "apellidos" => "Garc&#237;a"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Christian"
            "apellidos" => "Gortazar"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Rafael"
            "apellidos" => "Granados"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Juan"
            "apellidos" => "Mac&#237;as"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Nicol&#225;s"
            "apellidos" => "Merchante"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Jos&#233; Antonio"
            "apellidos" => "Oteo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "Mar&#237;a Teresa"
            "apellidos" => "P&#233;rez-Gracia"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "Juan Antonio"
            "apellidos" => "Pineda"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          12 => array:3 [
            "nombre" => "Antonio"
            "apellidos" => "Rivero"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          13 => array:3 [
            "nombre" => "David"
            "apellidos" => "Rodriguez-Lazaro"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">k</span>"
                "identificador" => "aff0055"
              ]
            ]
          ]
          14 => array:3 [
            "nombre" => "Francisco"
            "apellidos" => "T&#233;llez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">l</span>"
                "identificador" => "aff12"
              ]
            ]
          ]
          15 => array:3 [
            "nombre" => "Luis E&#46;"
            "apellidos" => "Morano-Amado"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">m</span>"
                "identificador" => "aff0060"
              ]
            ]
          ]
          16 => array:2 [
            "colaborador" => "Grupo redactor de GeHEP SEIMC"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#9674;</span>"
                "identificador" => "fn0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:13 [
          0 => array:3 [
            "entidad" => "Hospital Universitario Reina Sof&#237;a de C&#243;rdoba&#44; Instituto Maimonides de Investigaci&#243;n Biom&#233;dica de C&#243;rdoba &#40;IMIBIC&#41;&#44; Universidad de C&#243;rdoba&#44; Cordoba&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Complexo Hospitalario Universitario Santiago &#40;CHUS&#41; &#38; Universidad de Santiago&#44; Santiago de Compostela&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Centro Nacional de Microbiolog&#237;a&#44; Instituto de Salud Carlos III&#44; Madrid&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Consorcio General Hospital Universitario de Valencia&#44; Valencia&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Hospital Universitario San Cecilio&#44; Instituto de Investigaci&#243;n Biosanitaria IBS&#44; Granada&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Instituto de Investigaci&#243;n en Recursos Cineg&#233;ticos &#40;IREC-CSIC-UCLM&#41;&#44; Ciudad Real&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Hospital Universitario de Gran Canaria Dr&#46; Negr&#237;n&#44; Las Palmas de Gran Canaria&#44; Spain"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Hospital Universitario Virgen de Valme&#44; Instituto de Biomedicina de Sevilla &#40;IBIS&#41;&#44; Sevilla&#44; Spain"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Hospital Universitario San Pedro&#44; Logro&#241;o Centro de investigaci&#243;n Biom&#233;dica de La Rioja &#40;CIBIR&#41;&#44; Spain"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
          9 => array:3 [
            "entidad" => "Instituto de Ciencias Biom&#233;dicas&#44; Facultad de Ciencias de la Salud&#44; Universidad CEU Cardenal Herrera&#44; Valencia&#44; Spain"
            "etiqueta" => "j"
            "identificador" => "aff0050"
          ]
          10 => array:3 [
            "entidad" => "Facultad de Ciencias&#44; Universidad de Burgos&#44; Burgos&#44; Spain"
            "etiqueta" => "k"
            "identificador" => "aff0055"
          ]
          11 => array:3 [
            "entidad" => "Hospital Universitario Puerto Real&#44; C&#225;diz&#44; Spain"
            "etiqueta" => "l"
            "identificador" => "aff12"
          ]
          12 => array:3 [
            "entidad" => "Hospital Universitario &#193;lvaro Cunqueiro&#44; Instituto de Investigaci&#243;n Sanitaria Galicia Sur&#44; Vigo&#44; Spain"
            "etiqueta" => "m"
            "identificador" => "aff0060"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Resumen ejecutivo&#58; Documento de consenso del Grupo de Estudio de las Hepatitis V&#237;ricas perteneciente a la Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica sobre el diagn&#243;stico&#44; manejo y prevenci&#243;n de la infecci&#243;n por el virus de la hepatitis E"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 2148
            "Ancho" => 1583
            "Tamanyo" => 233590
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Proposed algorithm for the management of HEV infection&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Justification and scope</span><p id="par0005" class="elsevierStylePara elsevierViewall">Hepatitis E virus &#40;HEV&#41; infection is one of the main causes of acute hepatitis in both developed and developing countries&#46; This infectious disease has a high prevalence and incidence in Europe&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">1</span></a> HEV infection has a greater clinical impact in vulnerable populations&#44; such as immunosuppressed patients&#44; pregnant women&#44; and patients with underlying liver disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">2&#44;3</span></a> Thus&#44; the <span class="elsevierStyleItalic">World Health Organisation</span> &#40;WHO&#41; ranks it as one of the leading causes of death due to acute hepatitis of viral origin worldwide&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">4</span></a> However&#44; national and international recommendations for the screening&#44; diagnosis&#44; and treatment of HEV have not been developed &#40;EASL guidelines has been reported after submission of the present document&#41;&#44;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a> which makes it difficult to manage patients&#46; This&#44; combined with the fact that HEV infection is not a notifiable disease in most countries&#44; allows us to speculate that its incidence and clinical impact may be higher than expected&#46; The <span class="elsevierStyleItalic">European Food Safety Authority</span> &#40;EFSA&#41; has indicated that HEV infection is a major public health problem in Europe because the infection is transmitted efficiently by the consumption of contaminated animal foods &#40;mainly pork and game meat&#41;&#44; and there are no protocols or specific plans for prevention in animal production or in food production chains&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">6</span></a> Finally&#44; there are no recommendations for the screening of this disease in blood&#44; tissue&#44; or organ donors&#44; which may cause this route to be an important source of disease transmission&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">7&#44;8</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">By these reasons&#44; the <span class="elsevierStyleItalic">Grupo de Estudio de Hepatitis V&#237;ricas</span> &#40;GEHEP&#41; of the <span class="elsevierStyleItalic">Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica</span> &#40;SEIMC&#41; considered it very important to prepare a Consensus Document to help in decision making about the diagnosis&#44; clinical&#44; therapeutic management&#44; and prevention of HEV infection&#46; The panel of experts for the preparation of this document is composed of HEV infection experts in the areas of clinical management&#44; diagnostic microbiology&#44; food technology&#44; and veterinary medicine&#46; The recommendations in these guides are based on scientific evidence&#46; The strength of the recommendation and grading of the evidence that supports it are based on a modification of the criteria of the Infectious Diseases Society of America&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">9</span></a> According to these criteria&#44; each recommendation must always be offered &#40;A&#41;&#44; in general &#40;B&#41;&#44; or optionally &#40;C&#41;&#44; and must be based on data obtained from one or more randomised clinical trials with clinical or laboratory results &#40;I&#41;&#44; one or more nonrandomised trials or observational cohort studies &#40;II&#41;&#44; or the opinion of experts &#40;III&#41;&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Who should be screened for the hepatitis E virus&#63;</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Screening in patients with acute or chronic hepatitis</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Recommendations</span><p id="par0015" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">&#8226;</span><p id="par0020" class="elsevierStylePara elsevierViewall">All patients with acute hepatitis should be screened for HEV infection &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">&#8226;</span><p id="par0025" class="elsevierStylePara elsevierViewall">All patients with acute liver failure &#40;ALF&#41; should be screened for HEV infection &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">&#8226;</span><p id="par0030" class="elsevierStylePara elsevierViewall">In patients with known or recently diagnosed chronic liver disease with decompensation and&#47;or data suggestive of acute liver inflammation HEV should be screened &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">&#8226;</span><p id="par0035" class="elsevierStylePara elsevierViewall">HEV screening should be included in the diagnostic of chronic hepatitis &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">&#8226;</span><p id="par0040" class="elsevierStylePara elsevierViewall">In patients with unexplained liver disease HEV screening should performed &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">&#8226;</span><p id="par0045" class="elsevierStylePara elsevierViewall">In patients with suspected drug-induced hepatitis&#44; HEV screening should be performed &#40;BII&#41;&#46;</p></li></ul></p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Screening of HEV in blood and&#47;or organ donors</span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Recommendations</span><p id="par0050" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">&#8226;</span><p id="par0055" class="elsevierStylePara elsevierViewall">HEV screening should be performed on all organ donors&#44; living or deceased &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">&#8226;</span><p id="par0060" class="elsevierStylePara elsevierViewall">Studies on the prevalence of HEV infection in blood donations should be conducted across the different areas of blood bank influence to adapt HEV screening strategies to the prevalence of HEV infection in each area &#40;AII&#41;&#46;</p></li></ul></p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Screening of HEV in patients with extra-hepatic manifestations</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Recommendations</span><p id="par0065" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">&#8226;</span><p id="par0070" class="elsevierStylePara elsevierViewall">In patients with any of the extrahepatic clinical manifestations that have been associated with HEV infection &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#44; screening for HEV infection should performed&#44; even in the absence of liver abnormalities &#40;BII&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></li></ul></p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Screening in contacts of HEV cases</span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Recommendations</span><p id="par0075" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">&#8226;</span><p id="par0080" class="elsevierStylePara elsevierViewall">The study of the close contacts of a case with documented HEV infection is not recommended&#44; except in a case where they share a source of infection with the case &#40;AII&#41;&#46;</p></li></ul></p></span></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">How is hepatitis E virus infection diagnosed&#63;</span><p id="par0085" class="elsevierStylePara elsevierViewall">The virological markers for the diagnosis of HEV infection comprise components of the viral structure&#44; such as nucleic acid &#40;HEV-RNA&#41; and the viral antigen &#40;HEV-Ag&#41;&#44; and products of the host immune response&#44; such as Anti-HEV specific antibodies of classes IgA&#44; IgG&#44; and IgM&#46; These virological markers are the basis not only for diagnosis but also for monitoring treatment&#44; and they permit the characterisation of the natural history of hepatitis E in its different phases&#58; acute&#44; recent&#44; resolved or past&#44; and chronic&#46; The principal markers of acute HEV infection are HEV-RNA&#44; HEV-Ag&#44; Anti-HEV-IgM&#44; and -IgA&#59; increasing titres or low affinity of Anti-HEV-IgG antibodies are also indicative of acute HEV infection&#46; However&#44; these markers appear at different times&#44; persist for different periods&#44; and differ in their meaning in the clinical diagnosis&#46; Therefore&#44; regardless of whether the high titres or low affinity of Anti-HEV-IgG-specific antibodies can be considered suggestive of acute HEV infection&#44; their mere presence should not be considered a diagnostic criterion&#46; Consequently&#44; any diagnostic algorithm of HEV infection &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41; should be based mainly on the presence of Anti-HEV-IgM-specific antibodies and&#47;or the presence of HEV-Ag and HEV-RNA infectivity markers&#46; The diagnosis of chronic HEV infection is usually based almost exclusively on the presence of HEV-RNA in the blood or other body fluids for more than 3 months&#44; whereas that of resolved infection is characterised by the isolated presence of Anti-HEV-IgG antibodies&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Recommendations</span><p id="par0090" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0025"><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">&#8226;</span><p id="par0095" class="elsevierStylePara elsevierViewall">The diagnosis of acute HEV infection in immunocompetent individuals is based on the presence of Anti-HEV-IgM and&#47;or HEVRNA &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">&#8226;</span><p id="par0100" class="elsevierStylePara elsevierViewall">In laboratories that do not have adequate technology for molecular diagnosis&#44; despite its lower sensitivity&#44; it&#39;s recommended the detection of HEV-Ag as alternative&#44; as a direct method for the diagnosis of HEV infection &#40;AIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0065"><span class="elsevierStyleLabel">&#8226;</span><p id="par0105" class="elsevierStylePara elsevierViewall">Although it lacks diagnostic utility&#44; the characterisation of HEV at the genotype and subtype levels through direct or new generation sequencing and subsequent phylogenetic analysis may be important for studies of the molecular epidemiology of HEV infection &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0070"><span class="elsevierStyleLabel">&#8226;</span><p id="par0110" class="elsevierStylePara elsevierViewall">Quality control systems based on WHO standards should be established&#44; and reagents available for this purpose for the standardisation of the different results obtained in molecular and serological techniques should be determined &#40;BII&#41;&#46;</p></li></ul></p></span></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Who to treat and how to treat hepatitis E virus infection&#63;</span><p id="par0115" class="elsevierStylePara elsevierViewall">The treatment of HEV infection varies depending on the immunological situation of the patient and the clinical presentation of the infection &#40;acute vs chronic&#41;&#46; If indicated&#44; the treatment objective is to eradicate HEV&#44; which is determined by the achievement of a sustained viral response &#40;SVR&#41;&#44; defined as the absence of HEV-RNA at 12 weeks after the end of treatment&#46; For this&#44; the absence of HEV-RNA in both the serum and the faeces should be confirmed&#46; <a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a> shows the proposed algorithm for treatment of chronic HEV infection&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Treatment of acute hepatitis E</span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Recommendations</span><p id="par0120" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0030"><li class="elsevierStyleListItem" id="lsti0075"><span class="elsevierStyleLabel">&#8226;</span><p id="par0125" class="elsevierStylePara elsevierViewall">Antiviral treatment for acute hepatitis E should be considered in patients with liver cirrhosis or immunosuppression from any cause &#40;BII&#41;&#46; If treatment is indicated&#44; this will consist of RBV adjusted for weight &#40;1000<span class="elsevierStyleHsp" style=""></span>mg if &#60;75<span class="elsevierStyleHsp" style=""></span>kg or 1200<span class="elsevierStyleHsp" style=""></span>mg if &#62;75<span class="elsevierStyleHsp" style=""></span>kg&#41; for 3 months &#40;AII&#41;&#46;</p></li></ul></p></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Treatment of chronic hepatitis E</span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Recommendations</span><p id="par0130" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0035"><li class="elsevierStyleListItem" id="lsti0080"><span class="elsevierStyleLabel">&#8226;</span><p id="par0135" class="elsevierStylePara elsevierViewall">In patients with pharmacological immunosuppression and chronic hepatitis due to HEV&#44; immunosuppressive therapy should be reduced or discontinued if the clinical situation permits&#46; The persistence of HEV-RNA in the blood and faeces should be reevaluated at 12 weeks &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0085"><span class="elsevierStyleLabel">&#8226;</span><p id="par0140" class="elsevierStylePara elsevierViewall">In the case of persistent HEV-RNA after the reduction of immunosuppression or in those cases in which this measure is not feasible&#44; antiviral treatment should be initiated &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0090"><span class="elsevierStyleLabel">&#8226;</span><p id="par0145" class="elsevierStylePara elsevierViewall">In immunosuppressed patients of non-pharmacological causes&#44; such as HIV-infected individuals&#44; antiviral treatment should be considered from the beginning &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0095"><span class="elsevierStyleLabel">&#8226;</span><p id="par0150" class="elsevierStylePara elsevierViewall">The antiviral treatment will consist of the administration of RBV 600<span class="elsevierStyleHsp" style=""></span>mg per day for 12 weeks &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0100"><span class="elsevierStyleLabel">&#8226;</span><p id="par0155" class="elsevierStylePara elsevierViewall">At 4 weeks&#44; the presence of HEV-RNA in the serum should be evaluated&#44; and treatment should be prolonged to 24 weeks if the viral load is positive &#40;BII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0105"><span class="elsevierStyleLabel">&#8226;</span><p id="par0160" class="elsevierStylePara elsevierViewall">If the viral load at week 4 is negative&#44; the presence of HEV-RNA in the faeces and serum should be evaluated after 12 weeks of treatment&#44; and treatment can be suspended if HEV clearance has occurred &#40;BII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0110"><span class="elsevierStyleLabel">&#8226;</span><p id="par0165" class="elsevierStylePara elsevierViewall">In the case of viral persistence&#44; treatment should be continued until completing 24 weeks &#40;BII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0115"><span class="elsevierStyleLabel">&#8226;</span><p id="par0170" class="elsevierStylePara elsevierViewall">In all cases&#44; the presence of HEV-RNA in the faeces and serum should be evaluated 12 weeks after completing treatment &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0120"><span class="elsevierStyleLabel">&#8226;</span><p id="par0175" class="elsevierStylePara elsevierViewall">In the absence of SVR after a previous 12-week treatment&#44; retreatment with RBV should be considered for 24 weeks &#40;BIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0125"><span class="elsevierStyleLabel">&#8226;</span><p id="par0180" class="elsevierStylePara elsevierViewall">In those patients with an absence of SVR after treatment with RBV for 24 weeks&#44; there are no current alternative treatment options that can be recommended&#44; except for pegylated interferon in the specific scenario of liver transplantation &#40;CIII&#41;&#46;</p></li></ul></p></span></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Treatment of hepatitis E derived extrahepatic manifestations</span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Recommendations</span><p id="par0185" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0040"><li class="elsevierStyleListItem" id="lsti0130"><span class="elsevierStyleLabel">&#8226;</span><p id="par0190" class="elsevierStylePara elsevierViewall">Given the suspicion of extrahepatic manifestations related to HEV infection&#44; antiviral treatment with RBV can be considered following the same guidelines as for chronic hepatitis E &#40;CIII&#41;&#46;</p></li></ul></p></span></span></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">How should we follow-up on a patient diagnosed with hepatitis E virus infection&#63;</span><p id="par0195" class="elsevierStylePara elsevierViewall">HEV infection&#44; which depends in large part on the characteristics of the host and the virus itself&#44; can evolve in an acute or chronic manner as well as present a wide range of clinical manifestations&#44; ranging from asymptomatic or subclinical to fulminant hepatitis&#44; with or without extrahepatic manifestations&#46; Thus&#44; an individualised clinical follow up is required for each patient &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#41;&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Follow-up of acute infection</span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Recommendations</span><p id="par0200" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0045"><li class="elsevierStyleListItem" id="lsti0135"><span class="elsevierStyleLabel">&#8226;</span><p id="par0205" class="elsevierStylePara elsevierViewall">Follow up is recommended for immunocompetent patients with acute HEV infection over 12 weeks to determine HEV-RNA status at the end of this period &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0140"><span class="elsevierStyleLabel">&#8226;</span><p id="par0210" class="elsevierStylePara elsevierViewall">It is recommended that patients with acute HEV infection with clinical evidence of liver failure be admitted to an intensive care unit to start HEV treatment &#40;AIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0145"><span class="elsevierStyleLabel">&#8226;</span><p id="par0215" class="elsevierStylePara elsevierViewall">Weekly liver function tests and close foetal monitoring are recommended for pregnant women with acute HEV infection under gynaecological advice &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0150"><span class="elsevierStyleLabel">&#8226;</span><p id="par0220" class="elsevierStylePara elsevierViewall">Formula-feeding is recommended for women with acute or chronic HEV infection &#40;CIII&#41;&#46;</p></li></ul></p></span></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Follow-up of chronic infection</span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Recommendations</span><p id="par0225" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0050"><li class="elsevierStyleListItem" id="lsti0155"><span class="elsevierStyleLabel">&#8226;</span><p id="par0230" class="elsevierStylePara elsevierViewall">It is recommended that patients with chronic HEV infection and SVR with persistent immunosuppression receive biannual HEV-RNA treatment during the first year &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0160"><span class="elsevierStyleLabel">&#8226;</span><p id="par0235" class="elsevierStylePara elsevierViewall">The annual determination of HEV-RNA in the blood is recommended for immunocompromised patients in whom&#44; after reaching SVR&#44; the risk of exposure to HEV is maintained &#40;professional&#46;&#46;&#46;&#41;&#44; given the risk of reinfection &#40;BII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0165"><span class="elsevierStyleLabel">&#8226;</span><p id="par0240" class="elsevierStylePara elsevierViewall">Biannual ultrasound tests are recommended indefinitely for hepatocarcinoma screening amongst patients with chronic HEV infection and stage F3 or F4 liver fibrosis&#44; even after reaching SVR &#40;CIII&#41;&#46;</p></li></ul></p></span></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Follow-up of infection with extrahepatic manifestations</span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Recommendations</span><p id="par0245" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0055"><li class="elsevierStyleListItem" id="lsti0170"><span class="elsevierStyleLabel">&#8226;</span><p id="par0250" class="elsevierStylePara elsevierViewall">Treatment and follow up of HEV infection is recommended for cases of extrahepatic manifestations following the same recommendations cited for acute or chronic infection&#44; depending on the case &#40;CIII&#41;&#46;</p></li></ul></p></span></span></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">What measures should be recommended for preventing infection with the hepatitis E virus&#63;</span><p id="par0255" class="elsevierStylePara elsevierViewall">The risk of acquiring HEV infection varies depending on the geographical location and the genotypes circulating in each region&#46; Similar to all other communicable diseases&#44; the simplest measures for preventing them are based on avoiding contact with sources of infection&#46; In Europe&#44; the main HEV exposure routes come from the intake of pork products&#44; insufficiently cooked game animals &#40;particularly the livers&#41;&#44; and blood transfusions and their derivatives &#91;4&#44; 26&#44; 122&#93;&#46; In travellers to developing countries in Asia&#44; Africa&#44; and Latin America and in the inhabitants of these countries&#44; infections are also produced by this zoonotic route&#44; although the main source is contaminated water and the products contaminated by it&#44; causing large epidemic outbreaks&#46; Considering these facts&#44; it is essential to conduct information and awareness campaigns in the general population and amongst health workers&#44; emphasising the acquisition pathways&#46; Advice should be offered to the general population and&#44; particularly in our setting&#44; to immunosuppressed people and people who have chronic liver disease&#44; because of the high risk of the infection becoming chronic or of having an accelerated or serious course of infection&#46;</p><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">General measures in the general population and the immunosuppressed population</span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Recommendations</span><p id="par0260" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0060"><li class="elsevierStyleListItem" id="lsti0175"><span class="elsevierStyleLabel">&#8226;</span><p id="par0265" class="elsevierStylePara elsevierViewall">The prevention of HEV infection should be based on offering information aimed at avoiding contact with sources of infection &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0180"><span class="elsevierStyleLabel">&#8226;</span><p id="par0270" class="elsevierStylePara elsevierViewall">On trips to developing countries&#44; to avoid contact with HEV&#44; general hygienic practices should be adopted&#44; such as washing the hands with clean or sanitised water before handling food&#46; Do not drink water or consume ice of unknown purity&#46; The consumption of fruit not peeled by oneself and of raw foods in general should be avoided &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0185"><span class="elsevierStyleLabel">&#8226;</span><p id="par0275" class="elsevierStylePara elsevierViewall">In addition to adopting the basic hygienic measures recommended for the general population&#44; people at high risk of developing a severe course of infection or the chronification of it &#40;cirrhotic and transplanted&#41; must be specifically informed of the risk involved in eating pork products and undercooked game animals&#44; including sausages&#44; and to avoid the consumption of these products &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0190"><span class="elsevierStyleLabel">&#8226;</span><p id="par0280" class="elsevierStylePara elsevierViewall">People at high risk of developing a severe course of infection or the chronification of it should subject food to cooking-heating at a temperature<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>70<span class="elsevierStyleHsp" style=""></span>&#176;C for a minimum of 30<span class="elsevierStyleHsp" style=""></span>min &#40;AI&#41;&#46;</p></li></ul></p></span></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Measures in other populations and contacts</span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Recommendations</span><p id="par0285" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0065"><li class="elsevierStyleListItem" id="lsti0195"><span class="elsevierStyleLabel">&#8226;</span><p id="par0290" class="elsevierStylePara elsevierViewall">Given the serious and even fatal course that pregnant women may suffer&#44; women travelling to areas of high endemicity of HEV genotypes 1 and 2 should receive information and should adhere to hygienic standards to avoid contact with HEV &#40;AII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0200"><span class="elsevierStyleLabel">&#8226;</span><p id="par0295" class="elsevierStylePara elsevierViewall">Patients suffering from acute or chronic HEV infection should use barrier measures in their sexual relations &#40;AIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0205"><span class="elsevierStyleLabel">&#8226;</span><p id="par0300" class="elsevierStylePara elsevierViewall">Formula-feeding should be recommended in women with acute or chronic HEV infection &#40;CIII&#41;&#46;</p></li></ul></p></span></span><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0180">Vaccination</span><span id="sec0165" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0185">Recommendations</span><p id="par0305" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0070"><li class="elsevierStyleListItem" id="lsti0210"><span class="elsevierStyleLabel">&#8226;</span><p id="par0310" class="elsevierStylePara elsevierViewall">There is a recombinant vaccine marketed in China &#40;Hecolin&#174;&#41; that has been shown to be safe and effective in healthy people over 16 and under 65 years of age &#40;AI&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0215"><span class="elsevierStyleLabel">&#8226;</span><p id="par0315" class="elsevierStylePara elsevierViewall">Routine vaccination is not recommended in children under 16 years old&#44; people over 65 years old&#44; patients with chronic liver disease&#44; patients on solid organ transplant lists&#44; pregnant women&#44; or travellers &#40;CIII&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0220"><span class="elsevierStyleLabel">&#8226;</span><p id="par0320" class="elsevierStylePara elsevierViewall">Vaccination should be considered individually in people who plan to travel to an area where an epidemic is occurring &#40;e&#46;g&#46;&#44; aid workers and health workers&#41; &#40;CIII&#41;&#46;</p></li></ul></p></span></span></span><span id="sec0170" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0190">Conflict of interest</span><p id="par0325" class="elsevierStylePara elsevierViewall">There has been not funding from private institutions for the preparation of this document&#46; The members of the Consensus Document panel have agreed to participate voluntarily and issue a declaration of conflicts of interest that can be found in the full document report &#40;available at SEIMC web site&#41;&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres1283918"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1186520"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1283919"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1186519"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Justification and scope"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Who should be screened for the hepatitis E virus&#63;"
          "secciones" => array:4 [
            0 => array:3 [
              "identificador" => "sec0015"
              "titulo" => "Screening in patients with acute or chronic hepatitis"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0020"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "sec0025"
              "titulo" => "Screening of HEV in blood and&#47;or organ donors"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0030"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "sec0035"
              "titulo" => "Screening of HEV in patients with extra-hepatic manifestations"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0040"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "sec0045"
              "titulo" => "Screening in contacts of HEV cases"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0050"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0055"
          "titulo" => "How is hepatitis E virus infection diagnosed&#63;"
          "secciones" => array:1 [
            0 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "Recommendations"
            ]
          ]
        ]
        7 => array:3 [
          "identificador" => "sec0065"
          "titulo" => "Who to treat and how to treat hepatitis E virus infection&#63;"
          "secciones" => array:3 [
            0 => array:3 [
              "identificador" => "sec0070"
              "titulo" => "Treatment of acute hepatitis E"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0075"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "sec0080"
              "titulo" => "Treatment of chronic hepatitis E"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0085"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "sec0090"
              "titulo" => "Treatment of hepatitis E derived extrahepatic manifestations"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0095"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
          ]
        ]
        8 => array:3 [
          "identificador" => "sec0100"
          "titulo" => "How should we follow-up on a patient diagnosed with hepatitis E virus infection&#63;"
          "secciones" => array:3 [
            0 => array:3 [
              "identificador" => "sec0105"
              "titulo" => "Follow-up of acute infection"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0110"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "sec0115"
              "titulo" => "Follow-up of chronic infection"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0120"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "sec0125"
              "titulo" => "Follow-up of infection with extrahepatic manifestations"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0130"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
          ]
        ]
        9 => array:3 [
          "identificador" => "sec0135"
          "titulo" => "What measures should be recommended for preventing infection with the hepatitis E virus&#63;"
          "secciones" => array:3 [
            0 => array:3 [
              "identificador" => "sec0140"
              "titulo" => "General measures in the general population and the immunosuppressed population"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0145"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "sec0150"
              "titulo" => "Measures in other populations and contacts"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0155"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "sec0160"
              "titulo" => "Vaccination"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0165"
                  "titulo" => "Recommendations"
                ]
              ]
            ]
          ]
        ]
        10 => array:2 [
          "identificador" => "sec0170"
          "titulo" => "Conflict of interest"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2018-06-05"
    "fechaAceptado" => "2018-06-06"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1186520"
          "palabras" => array:10 [
            0 => "Hepatitis E"
            1 => "Zoonoses"
            2 => "Acute hepatitis"
            3 => "Chronic hepatitis"
            4 => "Pregnancy"
            5 => "Neurological disorders"
            6 => "Transplantation"
            7 => "Ribavirin"
            8 => "Pegylated interferon"
            9 => "Prevention"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1186519"
          "palabras" => array:10 [
            0 => "Hepatitis E"
            1 => "Zoonosis"
            2 => "Hepatitis aguda"
            3 => "Hepatitis cr&#243;nica"
            4 => "Embarazo"
            5 => "Alteraciones neurol&#243;gicas"
            6 => "Trasplante"
            7 => "Ribavirina"
            8 => "Interfer&#243;n pegilado"
            9 => "Prevenci&#243;n"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Hepatitis E virus &#40;HEV&#41; infection is one of the main causes of acute hepatitis in both developed and developing countries&#46; This infectious disease has a high prevalence and incidence in Europe&#46; HEV infection has a greater clinical impact in vulnerable populations&#44; such as immunosuppressed patients&#44; pregnant women and patients with underlying liver disease&#46; Therefore&#44; the Study Group for Viral Hepatitis &#40;<span class="elsevierStyleItalic">Grupo de Estudio de Hepatitis V&#237;ricas</span>&#44; GEHEP&#41; of the Spanish Society of Infectious Diseases and Clinical Microbiology &#40;<span class="elsevierStyleItalic">Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica</span>&#44; SEIMC&#41; believed it very important to prepare a consensus document to help in decision-making regarding diagnosis&#44; clinical and therapeutic management&#44; and prevention of HEV infection&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La infecci&#243;n por el virus de la hepatitis E &#40;VHE&#41; es una de las principales causas de hepatitis aguda tanto en pa&#237;ses desarrollados como en v&#237;as de desarrollo&#44; situ&#225;ndose como una enfermedad infecciosa de alta prevalencia e incidencia en Europa&#46; La infecci&#243;n por el VHE tiene mayor impacto cl&#237;nico en poblaciones especialmente vulnerables&#44; como pacientes inmunodeprimidos&#44; mujeres embarazadas y pacientes con hepatopat&#237;a base&#46; Por todo ello&#44; desde el Grupo de Estudio de las Hepatitis V&#237;ricas &#40;GeHEP&#41; de la Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica &#40;SEIMC&#41; se considera de gran relevancia la elaboraci&#243;n de un Documento de Consenso que sirva de ayuda en la toma de decisiones sobre el diagn&#243;stico&#44; manejo cl&#237;nico-terap&#233;utico y la prevenci&#243;n de la infecci&#243;n por el VHE&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:3 [
        "etiqueta" => "&#9674;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0020">The complete consensus statement is as supplementary material in <a class="elsevierStyleCrossRef" href="#sec0175">Appendix A</a>&#46;</p>"
        "identificador" => "fn0005"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="par0335" class="elsevierStylePara elsevierViewall">The following are the supplementary data to this article&#58;<elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>"
            "etiqueta" => "Appendix A"
            "titulo" => "Supplementary data"
            "identificador" => "sec0180"
          ]
        ]
      ]
    ]
    "multimedia" => array:5 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1881
            "Ancho" => 1583
            "Tamanyo" => 179659
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Recommended management algorithm for the treatment of chronic hepatitis E&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 2148
            "Ancho" => 1583
            "Tamanyo" => 233590
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Proposed algorithm for the management of HEV infection&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acute pancreatitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Haematological manifestations&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Thrombopenia&#44; haemolysis&#44; aplastic anaemia&#44; cryoglobulinemia&#44; monoclonal gammopathy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Autoimmune phenomena&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Membranous glomerulonephritis&#44; Henoch-Sch&#246;nlein purpura&#44; arthralgia&#44; skin rash&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CNS neurological syndromes&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Transverse acute myelitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Acute meningoencephalitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Aseptic meningitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Amyotrophic neuralgia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Pseudotumour cerebri&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Bilateral pyramidal syndrome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PNS neurological syndromes&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Guillain-Barr&#233; syndrome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Cranial nerve paralysis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8226; Peripheral neuropathy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2199453.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Extrahepatic manifestations of HEV infection&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Anti-HEV-IgM<a class="elsevierStyleCrossRefs" href="#tblfn0005"><span class="elsevierStyleSup">a&#44;c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="3" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Positive</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="4" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative</th></tr><tr title="table-row"><th class="td-with-role" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">HEV-RNA and&#47;or HEV-Ag<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Positive&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Positive</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Anti-HEV-IgG<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Positive&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Positive&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Positive&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Interpretation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acute infection Chronic infection &#40;RNA&#43; &#62;3 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recent infection&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cross-reactivity<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acute infectionPossible reinfection&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Window period Chronic infection &#40;RNA&#43; &#62;3 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Past infection&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Absence of infection&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2199452.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Serum and&#47;or plasma&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Serum&#44; plasma&#44; CSF&#44; faeces&#44; urine&#44; etc&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Anti-HEV-IgM reactivity should be confirmed with immunoblotting and a subsequent seroconversion study&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Diagnostic algorithm for HEV infection&#46;</p>"
        ]
      ]
      4 => array:5 [
        "identificador" => "upi0005"
        "tipo" => "MULTIMEDIAECOMPONENTE"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "Ecomponente" => array:2 [
          "fichero" => "mmc1.pdf"
          "ficheroTamanyo" => 723773
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:9 [
            0 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatitis E virus infection in Europe&#58; surveillance and descriptive epidemiology of confirmed cases&#44; 2005 to 2015"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46;J&#46; Aspinall"
                            1 => "E&#46; Couturier"
                            2 => "M&#46; Faber"
                            3 => "B&#46; Said"
                            4 => "S&#46; Ijaz"
                            5 => "L&#46; Tavoschi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Euro Surveill"
                        "fecha" => "2017"
                        "volumen" => "22"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatitis E virus &#40;HEV&#41; infection in patients with cirrhosis is associated with rapid decompensation and death"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Kumar Acharya"
                            1 => "P&#46; Kumar Sharma"
                            2 => "R&#46; Singh"
                            3 => "S&#46; Kumar Mohanty"
                            4 => "K&#46; Madan"
                            5 => "J&#46; Kumar Jha"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2006.09.016"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2007"
                        "volumen" => "46"
                        "paginaInicial" => "387"
                        "paginaFinal" => "394"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17125878"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46; Patra"
                            1 => "A&#46; Kumar"
                            2 => "S&#46;S&#46; Trivedi"
                            3 => "M&#46; Puri"
                            4 => "S&#46;K&#46; Sarin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-147-1-200707030-00005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Intern Med"
                        "fecha" => "2007"
                        "volumen" => "147"
                        "paginaInicial" => "28"
                        "paginaFinal" => "33"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17606958"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "World Health Organization&#46; Global hepatitis report&#44; 2017&#46; Available from&#58; <a target="_blank" href="http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/">http&#58;&#47;&#47;www&#46;who&#46;int&#47;hepatitis&#47;publications&#47;global-hepatitis-report2017&#47;en&#47;</a>&#46;"
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EASL Clinical Practice Guidelines on hepatitis E virus infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "European Association for the Study of the Liver"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2018.03.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2018"
                        "volumen" => "68"
                        "paginaInicial" => "1256"
                        "paginaFinal" => "1271"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29609832"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Food Safety Authority&#46; Public health risks associated with hepatitis E virus &#40;HEV&#41; as a food-borne pathogen&#46; Available from&#58; <a target="_blank" href="https://www.efsa.europa.eu/en/efsajournal/pub/4886">https&#58;&#47;&#47;www&#46;efsa&#46;europa&#46;eu&#47;en&#47;efsajournal&#47;pub&#47;4886</a>&#46;"
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatitis E and blood donation safety in selected European countries&#58; a shift to screening&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Domanovi&#263;"
                            1 => "R&#46; Tedder"
                            2 => "J&#46; Bl&#252;mel"
                            3 => "H&#46; Zaaijer"
                            4 => "P&#46; Gallian"
                            5 => "C&#46; Niederhauser"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Euro Surveill"
                        "fecha" => "2017"
                        "volumen" => "22"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Summary of the British Transplantation Society UK guidelines for hepatitis E and solid organ transplantation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; McPherson"
                            1 => "A&#46;M&#46; Elsharkawy"
                            2 => "M&#46; Ankcorn"
                            3 => "S&#46; Ijaz"
                            4 => "J&#46; Powell"
                            5 => "I&#46; Rowe"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/TP.0000000000001908"
                      "Revista" => array:6 [
                        "tituloSerie" => "Transplantation"
                        "fecha" => "2018"
                        "volumen" => "102"
                        "paginaInicial" => "15"
                        "paginaFinal" => "20"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28795981"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Guide to development of practice guidelines"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "M&#46;A&#46; Kish"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Infect Dis"
                        "fecha" => "2001"
                        "volumen" => "32"
                        "paginaInicial" => "841"
                        "paginaFinal" => "844"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/0213005X/0000003800000001/v1_202001061158/S0213005X18302271/v1_202001061158/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "8681"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Documento de consenso"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/0213005X/0000003800000001/v1_202001061158/S0213005X18302271/v1_202001061158/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X18302271?idApp=UINPBA00004N"
]

Información del artículo

ISSN: 0213005X
Idioma original: Inglés

DOI:10.1016/j.eimc.2018.06.014

Datos actualizados diariamente

año/Mes	Html	Pdf	Total

2024 Octubre	331	5	336
2024 Septiembre	477	14	491
2024 Agosto	354	9	363
2024 Julio	366	7	373
2024 Junio	336	6	342
2024 Mayo	469	22	491
2024 Abril	453	22	475
2024 Marzo	679	20	699
2024 Febrero	716	20	736
2024 Enero	1329	16	1345
2023 Diciembre	5025	22	5047
2023 Noviembre	2345	29	2374
2023 Octubre	1964	32	1996
2023 Septiembre	1257	14	1271
2023 Agosto	1039	12	1051
2023 Julio	929	22	951
2023 Junio	1018	32	1050
2023 Mayo	707	23	730
2023 Abril	392	29	421
2023 Marzo	1845	58	1903
2023 Febrero	2373	14	2387
2023 Enero	2518	16	2534
2022 Diciembre	2463	15	2478
2022 Noviembre	458	17	475
2022 Octubre	685	11	696
2022 Septiembre	1635	27	1662
2022 Agosto	363	23	386
2022 Julio	185	13	198
2022 Junio	285	17	302
2022 Mayo	214	23	237
2022 Abril	504	10	514
2022 Marzo	577	26	603
2022 Febrero	257	10	267
2022 Enero	214	14	228
2021 Diciembre	412	21	433
2021 Noviembre	1066	11	1077
2021 Octubre	1619	29	1648
2021 Septiembre	339	17	356
2021 Agosto	333	23	356
2021 Julio	712	24	736
2021 Junio	1149	34	1183
2021 Mayo	2081	12	2093
2021 Abril	1108	29	1137
2021 Marzo	355	29	384
2021 Febrero	155	28	183
2021 Enero	259	28	287
2020 Diciembre	150	30	180
2020 Noviembre	119	21	140
2020 Octubre	110	12	122
2020 Septiembre	203	19	222
2020 Agosto	289	24	313
2020 Julio	369	25	394
2020 Junio	290	8	298
2020 Mayo	187	3	190
2020 Abril	162	3	165
2020 Marzo	245	13	258
2020 Febrero	195	22	217
2020 Enero	362	268	630
2019 Diciembre	0	4	4
2019 Noviembre	0	2	2
2019 Octubre	0	1	1
2019 Septiembre	0	4	4
2019 Julio	1	4	5
2019 Junio	0	2	2
2019 Marzo	0	4	4
2018 Diciembre	0	2	2
2018 Noviembre	0	6	6
2018 Octubre	0	2	2
2018 Septiembre	0	2	2
2018 Agosto	0	9	9
2018 Julio	0	1	1

Mostrar todo

Indexada en:

Síguenos:

Suscribirse:

Estadísticas

Indexada en:

Síguenos:

Suscribirse:

Estadísticas

Suscríbase a la newsletter